H. Lundbeck A/S and Contera Pharma Form Strategic Alliance to Advance RNA-Based Therapies for Neurological Diseases

Strategic Insights -

H. Lundbeck A/S, a leading Danish pharmaceutical company, and Contera Pharma, a Danish clinical-stage biotech company, have joined forces to accelerate the development of oligonucleotide-based medicines for serious neurological conditions. The strategic research collaboration leverages Lundbeck's extensive neuroscience experience and Contera Pharma's RNA discovery platforms to explore novel RNA-targeting approaches. This partnership aims to expand Lundbeck's research portfolio and build its neurodegeneration treatment pipeline.

Key Takeaways:

  • The strategic alliance between H. Lundbeck A/S and Contera Pharma focuses on discovering and developing oligonucleotide-based medicines for serious neurological conditions.
  • The companies will explore novel RNA-targeting approaches using Contera Pharma's RNA discovery platforms, including AttackPoint discovery, OligoDisc, and SpliceMatrix.
  • Contera Pharma will receive an upfront payment, full research funding per target, and be eligible for milestone payments and tiered royalties on future net sales.
  • H. Lundbeck retains options to advance promising candidates into later-stage clinical development and global commercialization.
  • The partnership is part of Lundbeck's strategy to broaden its research portfolio and build its neurodegeneration treatment pipeline.
  • Contera Pharma's RNA discovery engine is validated by the deal, which will accelerate its mission to deliver innovative oligonucleotide therapies for patients with high unmet needs.

Statistics:

  • 70+ years of neuroscience experience that Lundbeck will leverage in the partnership.
  • 3 RNA discovery platforms (AttackPoint discovery, OligoDisc, and SpliceMatrix) used by Contera Pharma in the collaboration.
  • 1 upfront payment received by Contera Pharma.
  • Tiered royalties on future net sales for Contera Pharma.

Sources:

  • H. Lundbeck A/S
  • Contera Pharma
  • M2 Communications (M2 EQUITYBITES-Oct 20, 2025)